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Introduction. Pain is a frequent symptom in oncology, approximately 50% of cancer patients have pain at some moment in their
disease, and increase by 75–90% in advanced stages. Pain may be associated with the tumor, with treatment or be related with
other causes. Presents an important physical,mental and social impact, so it is important to give anadequate analgesic treatment.
Objective. To analyze the pain incidence, intensity and treatment in our Radiotherapy Oncology unit.
Materials and methods. An observational study has been realized interviewing 200 patients of our unit. We have made them several
questions about pain: presence/absence, cause, location, days with pain, intensity according to VAS and treatment.
Results. Of the 200 patients, 120 were men and 80 were women, with a mean age of 64 years (26–87). 147 patients were asymp-
tomatic (73.5%) and 53 had pain (26.5%), pain was related to the disease and/or the treatment to 79.2% of cases and independent
to 20.8%. Of the 53 patients with pain, 69.8% were taking medication (ﬁrst step: 45.9%, second step: 10.9% and third step: 43.2%).
We analyzed VAS maximum, middle and minimum by steps of analgesic: ﬁrst step (6.4/4/1.6), second step (6/4.2/2.2), and third
step (6.6/2.3/2.3).
Conclusion. Most of our patients have no pain. Those who are symptomatic are mainly palliative or head and neck tumours. They
have an average of days a week with pain of 6 (1–7) and a mode of 7. Analyzing the patients by steps, we observe that in the
ﬁrst and second, only one patient in each group is well treated, others have a maximum VAS above 4; would be necessary to
step up. Third step patients also show a high maximum average VAS, could be to have low doses, absence of rescue analgesia or
adjuvant, or they need a fourth step using invasive techniques.
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Introduction. Tapentadol is a centrally acting analgesic with a dual mechanism of action ( receptor agonism and inhibiting the
reuptake of norepinephrine).
Objective. To evaluate the efﬁcacy of Tapentadol in cancer patients with chronic and/or acute pain.
Patients and methods. Between October 2011–September 2012, 28 patients were treated with Tapentadol in 3 Departments. Retro-
spective descriptive analysis of treatment with Tapentadol (SPSS 20.0).
Results. Patients were 10 women (35.7%) and 18 men (64.3%). Age range 28–85 years (mean=60.8). The 17.8% of patients stopped
treatment because of death, 7.1% because of improvement and 3.6% because of pruritus. The 71.4% continued treatment. The
14.3% increased dose to achieve analgesia. (a) Primary tumor type: The most common cancer were 21.4% lungs, 21.4% head
and neck, 17.8% breast. (b) Pain was due to: 32.1% tumour, 28.6% bone metastases, 14.3% benign problems, 10.7% induced by
RT, 7.1% visceral metastases and 7.1% neuropathic pain. (c) VAS before and after treatment: the mean VAS pretreatment=7.2
and posttreatment=3 (4.2 points difference). The 71.4% of patients progressed to mild pain (VAS=<4). (d) Tapentadol mean
dose=114. 3mg. The dose most used was 50mg (42.9%). (e) Other medications associated: none (17.8%), rapid onset fentanyl
(60.7%), antiepileptics (28.6%), steroids (28.6%) NSAIDs (21.4%), morphine (7.1%), anxiolytics (7.1%), antidepressants (3.6%), 5%
lidocaine (3.6%) and acupuncture (3.6%) f) Analgesic efﬁcacy: 100% of cases. Mean analgesic = 41.7% and maximum=87.5%. (g)
Side effects: well tolerated with mild effects (pruritus, constipation) in 3 cases (10.7%).
Conclusions. Our data support the use of Tapentadol pain in cancer patients with moderate to severe chronic or acute pain (VAS>
5). Tapentadol is an effective pain reliever with few side effects.
http://dx.doi.org/10.1016/j.rpor.2013.03.588
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Introduction. Radiotherapy (RT) is the modality of cancer treatments to which less attention has been paid with respect to psy-
chological problems. Thus, there may be signiﬁcant psychopathological symptoms and an emotional response due to lack of
information or that is inappropriate (Die Trill, 2003; Cruzado and Olivares, 2005).
